Nichol F R, Weed S D, Underwood G E
Antimicrob Agents Chemother. 1976 Mar;9(3):433-9. doi: 10.1128/AAC.9.3.433.
2-Amino-5-bromo-6-methyl-4-pyrimidinol (U-25,166) induced high levels of circulating interferon in mice when administered either parenterally or orally. Peak titers of interferon were found in the serum between 6 and 12 h after inoculation of the drug. Lower but significant levels of interferon were found in rat serum after administration of U-25,166 by either the intraperitoneal or oral route, and good levels of circulating interferon were observed in cats after oral treatment. Repeated intraperitoneal doses (50 mg/kg) of U-25,166 protected mice against intranasal encephalomyocarditis virus challenge. The minimal effective acute oral dose for antiviral activity was approximately 250 mg/kg. This was also the minimal dose that produced detectable levels of interferon. Maximum tolerated doses in mice were four to six times the minimal effective doses. A single oral treatment was protective in mice against challenge virus inoculated 24 h later. The compound protected mice from challenge with high levels of encephalomyocarditis virus, up to 20,000 mean lethal doses. Antiviral activity in mice was retained when certain minor substitutions were made in the U-25,166 structure.
2-氨基-5-溴-6-甲基-4-嘧啶醇(U-25,166)经肠胃外或口服给药后,可在小鼠体内诱导产生高水平的循环干扰素。接种该药物后6至12小时,血清中干扰素达到峰值效价。通过腹腔内或口服途径给予U-25,166后,在大鼠血清中发现了较低但显著水平的干扰素,口服治疗后在猫体内观察到了良好水平的循环干扰素。重复腹腔内给予U-25,166(50毫克/千克)可保护小鼠免受鼻内脑心肌炎病毒攻击。抗病毒活性的最小有效急性口服剂量约为250毫克/千克。这也是产生可检测水平干扰素的最小剂量。小鼠的最大耐受剂量是最小有效剂量的四至六倍。单次口服治疗对24小时后接种攻击病毒的小鼠具有保护作用。该化合物可保护小鼠免受高水平脑心肌炎病毒(高达20,000平均致死剂量)的攻击。当对U-25,166结构进行某些微小取代时,小鼠体内仍保留抗病毒活性。